Generation Bio Co. (GBIO)

$6.7

+0.14 (+2.13%)
Rating:
Recommendation:
-
Symbol GBIO
Price $6.7
Beta 2.866
Volume Avg. 0.39M
Market Cap 382.490M
Shares () -
52 Week Range 3.96-28.665
1y Target Est -
DCF Unlevered GBIO DCF ->
DCF Levered GBIO LDCF ->
ROE -32.65% Strong Sell
ROA -28.96% Sell
Operating Margin -
Debt / Equity 25.82% Neutral
P/E -
P/B 1.08 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GBIO news


Dr. Cameron Geoffrey McDonough
Healthcare
Biotechnology
NASDAQ Global Select

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.